TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 juil. 2024 16h07 HE
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
22 juil. 2024 08h20 HE
|
SciSparc Ltd
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
The Alberta Cancer Foundation’s Enbridge Tour Alberta for Cancer Passes $100 Million Milestone in its 16th Year
20 juil. 2024 09h45 HE
|
Alberta Cancer Foundation
The 16th annual Enbridge Tour Alberta for Cancer in support of the Alberta Cancer Foundation marks $100M in total funds raised.
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
17 juil. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
11 juil. 2024 12h21 HE
|
Tevogen Bio Inc
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
11 juil. 2024 12h00 HE
|
Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
U.S. Colorectal Cancer Screening Market is Expected to Reach US$ 10,618.9 Million by 2031, CoherentMI
11 juil. 2024 04h00 HE
|
CMI
Burlingame, July 11, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, U.S. Colorectal Cancer Screening Market is estimated to value at US$ 5,952.2 Million in the year 2024, and is...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10 juil. 2024 08h05 HE
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
10 juil. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
ImCheck Appoints Stephan Braun as Chief Medical Officer
09 juil. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...